The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function in Patients With Mild-to-Moderate Hypertension

The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function in Patients With Mild-to-Moderate Hypertension - J-ELAN

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000319

Enrollment

300

Registered

2006-02-01

Start date

2005-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive heart disease

Interventions

treatment with angiotensin II type 1 receptor blocker treatment with calcium channel blocker

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: •Mild to moderate hypertension (systolic blood pressure with 140 mmHg or over and with 200 mmHg or less, diastolic blood pressure with 90 mmHg or over and with 110 mmHg or less, •Presence of LV hypertrophy (a ratio of LV mass to body surface area (LV mass index) with 120 g/m2 or over in men and with 105 g/m2 or over in women, or LV wall thickness > 11 mm. •LV diastolic dysfunction (a ratio of peak early to late diastolic filling velocities (E/A) 1.5, an E-wave deceleration time 280 msec, isovolumic relaxation time 105 msec) •LV ejection fraction with 50% or over

Exclusion criteria

Exclusion criteria: •History of a life-threatening adverse event induced by ARB or CCB •Pregnant woman •Serious liver dysfunction (aspartate aminotransferase or alanine aminotransferase more than 10 times of normal upper limit) •Serum creatinine > 1.8 mg/dl, known bilateral renal artery stenosis, single kidney, renal sclerosis •Secondary hypertension, malignant hypertension, hypertensive encephalopathy •Cardiovascular or cerebrovascular accidents within the last 6 months •Patients with angina pectoris who need CCB or beta-blocker •Significant aortic stenosis (peak transaortic valve pressure gradient > 20 mmHg) •Important aortic or mitral regurgitation in the investigators opinion •Patients with other diseases which affect the serum levels of carboxy-terminal telopeptide of collagen type I (CITP) and carboxy-terminal of procollagen type III (PIIIP) •Prescription of ACEI or ARB within 5 months •Prescription of beta-blocker or CCB within 4 weeks

Design outcomes

Primary

Measure	Time frame
LV diastolic function	—

Secondary

Measure	Time frame
carotid artery atherosclerosis BNP PIIIP CITP high sensitivity C-reactive protein	—

Countries

Japan

Contacts

Public ContactKazuhiro Yamamoto

Osaka University Graduate School of Medicine Department of Cardiovascular Medicine

kazuhiro@medone.med.osaka-u.ac.jp06-6879-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026